Corroborating these findings, Huang et al. reported a downregulated expression of FASN in patients with prostate cancer who were treated with androgen deprivation therapy and chemotherapy [137], thus suggesting FASN as a molecular target against prostate cancer. Here, FASN is linked to prostate cancer.